August 23, 2016

Verlyx Pharma receives U.S. patent for its lead product VLX103 for the treatment of liver diseases or conditions

Montréal – August 23, 2016 – Verlyx Pharma Inc., a specialty pharmaceutical company developing innovative therapies for the treatment of liver and gastrointestinal inflammatory diseases, announces the issue by the United States Patent and Trademark Office on June 28, 2016 of a new patent covering the company’s product pipeline for the treatment of liver conditions, such as non-alcoholic steatohepatitis (NASH), and alcoholic steatohepatitis (ASH).

The new patent, US 9,375,411 B2, entitled “USES AND METHODS FOR THE TREATMENT OF LIVER DISEASES OR CONDITIONS” strengthens Verlyx’s patent position around its lead compound, VLX103.

“We are delighted that the U.S. Patent and Trademark Office has recognized the innovative nature of our therapeutic approach in the field of liver diseases through the issuance of this patent,” commented Dr. Pierre Falardeau, President and CEO of Verlyx Pharma. “With an expiry date in December 2033, the issuance of this U.S. patent provides Verlyx Pharma with an exceptional exclusivity period, given that our lead product VLX103 is already Phase 2-ready,” added Dr. Falardeau.

Verlyx has successfully completed a phase 1 with VLX103 and is now ready to initiate its phase 2 for the treatment of NASH.

About Verlyx Pharma

Verlyx Pharma Inc. is a specialty pharmaceutical company focused on the development of innovative therapies for the treatment of liver and gastrointestinal inflammatory diseases with high unmet needs. Verlyx’s lead product, VLX103, is a proprietary oral product that combines hepatoselective and hepatoprotective properties. The company is conducting an ambitious research and development program aimed at important unmet needs in the field of liver diseases, including Non-Alcoholic Steatohepatitis (NASH) and Alcoholic Steatohepatitis (ASH). Additional information about the company can be obtained on its website: www.verlyx.com.